Nykode Therapeutics has released new preclinical and manufacturing data for VB10.NEO, an individualized neoantigen therapy. The results indicate that their DNA-based platform induces stronger and more durable T-cell responses compared to traditional peptide vaccines. Additionally, the company reported improvements in manufacturing scalability and timelines, positioning the asset for strategic partnerships.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.